Dror Bashan
Known title: President and CEOCIK: 0001781450
Dror Bashan's purchase track record
How the stock did after each of Dror Bashan's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since April 11, 2022
Stock higher 6 months later
33%
3 months: 67%
Median 6-month return
-22.6%
3 months: +0.7%
Beat the S&P 500
33%
median -9.5% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/19/2025 | PLX | $101K | +23.7% | +24.9% | +9.3% |
| 10/19/2023 | PLX | $90K | +0.7% | -22.6% | +17.1% |
| 4/11/2022 | PLX | $102K | -21.3% | -27.7% | -18.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PLX | ▲ Buy | Open Market | 56,000 | $101K | 12/19/2025 | View on chart |
| PLX | ▲ Buy | Grant | 195,000 | — | 9/3/2025 | View on chart |
| PLX | ▲ Buy | Grant | 263,960 | — | 4/1/2024 | View on chart |
| PLX | ▲ Buy | Open Market | 48,387 | $68K | 10/19/2023 | View on chart |
| PLX | ▲ Buy | Open Market | 16,129 | $23K | 10/19/2023 | View on chart |
| PLX | ▲ Buy | Grant | 800,000 | — | 8/15/2023 | View on chart |
| PLX | ▲ Buy | Open Market | 68,000 | $102K | 4/11/2022 | View on chart |
| PLX | ▲ Buy | Grant | 637,531 | — | 2/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
PLX: No direct news; broader market analyst moves noted
Recent news coverage focuses on analyst actions for other companies like Netflix and SanDisk, with no specific updates reported for Protalix BioTherapeutics. The stock currently trades within its 52-week range of $1.60 to $3.19, holding above the identified support level of $2.31. While technical signals show some divergence, the lack of company-specific headlines keeps the immediate news impact low.
PLX: No direct news; broader market analyst moves noted. Recent news coverage focuses on analyst actions for other companies like Netflix and SanDisk, with no specific updates reported for Protalix BioTherapeutics. The stock currently trades within its 52-week range of $1.60 to $3.19, holding above the identified support level of $2.31. While technical signals show some divergence, the lack of company-specific headlines keeps the immediate news impact low.